A real-world cohort study compares efficacy and safety of rituximab and inebilizumab in neuromyelitis optica spectrum disorder patients, indicating distinct safety concerns.
In our real-world study of 276 patients, rituximab and inebilizumab demonstrated comparable efficacy in the medium term but differed in their safety profiles, with a significantly higher incidence of infusion-related reactions observed in the rituximab group.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: